Skip to main content
Cancer Medicine logoLink to Cancer Medicine
. 2022 Mar 21;11(17):3272–3281. doi: 10.1002/cam4.4701

Elevated air quality index and fine particulate matter levels contribute to the poor prognosis and progression of nonsmall‐cell lung cancer: A cohort study combined with external validation

Jing Li 1, Xiaoying Wei 1, Ling Gu 2, Linya Qiu 3, Mengqi Xiang 4, Huachuan Zhang 5, Lei Xia 1, Wenying Pan 1, Zhenyu Yang 1, Xiaoli Zhou 1, Daxiong Zeng 1,✉, Junhong Jiang 1,✉
PMCID: PMC9468439  PMID: 35312179

Abstract

Background

Poor air quality can result in a variety of respiratory disorders. However, the air quality index (AQI) and the level of fine particulate matter (PM2.5) on the progression and prognosis of nonsmall‐cell lung cancer (NSCLC) are unclear.

Methods

We launched a cohort study focused on the relationship between air quality and overall survival as well as progression, incorporating data from 590 patients with NSCLC in our medical center between November 1, 2013 and March 1, 2016. Forty‐nine patients from Sichuan Cancer Hospital were used for validation.

Results

Cases with poorer AQI 6 months before NSCLC diagnosis were more likely to progress to stage III to IV NSCLC than controls (OR = 2.61, 95% CI 1.35–5.24, p = 0.005). Similarly, if exposed to high levels of PM2.5 during these 6 months, overall survival was poor (HR [95% CI] = 1.53 [1.13, 2.07], p = 0.006). According to multivariate analysis, age, gender, KPS, PM2.5, hyperlipemia, and NSCLC stage were independent risk factors of overall survival. A predictive model developed by these factors above yielded a favorable agreement (C‐index = 0.758) on the calibration curve. External validation was conducted by 46 patients from Sichuan Cancer Hospital displaying an AUC of 0.724 (0.684–0.763).

Conclusions

PM2.5 and AQI levels affect disease progression and long‐term survival in NSCLC patients. An overall survival prediction model based on the PM2.5 level can help clinicians predict the risk of death in NSCLC.

Keywords: air quality index, NSCLC, PM2.5, prediction model, prognosis

1. INTRODUCTION

Air pollution, especially PM2.5, is a risk factor for many respiratory diseases. 1 Elevated levels of PM2.5 can be found in air pollution environments worldwide. This can also be seen in many environments where smoking and cooking or heating through solid fuels is practiced.. 2 , 3 PM2.5 can penetrate deep into the lungs and be deposited in the small airways, 4 , 5 whose physiology is vital for triggering respiratory diseases. 6 Anatomically, the small airway has a small cross‐sectional area with an internal diameter of <2 mm. 7 Small airways tract impairment contributes significantly to airflow obstruction 8 , 9 and airway inflammation, 10 , 11 , 12 both risk factors for lung cancer. However, PM2.5 is related to increased oxidative stress and lung inflammation. 13 , 14

Lung cancer is a relatively common tumor and a significant cause of death from malignancy worldwide. 15 , 16 Chemotherapy for NSCLC is less effective than for SCLC, and thus approximately 50% of patients with NSCLC face cancer recurrence even if surgical resection is performed at early diagnosis. 17 However, despite numerous clinical studies, 5‐year overall survival rates remain as low as 14%–17% for all stages of NSCLC 18 , 19 and even lower (6%) for SCLC. 20 For the epidemiological studies and Virchow hypothesis, people prone to chronic inflammation are at elevated risk of NSCLC, and underlying inflammatory and infections responses are linked to nearly 20% of deaths worldwide. 21 And air pollution has a catalytic effect on respiratory tract inflammation. 1 , 22 To our knowledge, few investigations have shown whether reduced PM2.5 can be related to long‐term prognosis as well as tumor progression in lung cancer.

To explore the correlation between air pollutants from different tumors and the progression and long‐term outcome of lung cancer patients, we launched a cohort study to obtain the air quality of patients for 6 months before their diagnosis. We correlated it with the survival status and disease progression of NSCLC patients to construct a survival prediction model. Data from Sichuan Cancer Hospital were also collected for external validation.

2. METHODS

2.1. Patients

We launched a cohort investigation that included data from 590 patients with NSCLC at our medical center between November 1, 2013 and March 1, 2016. The deadline for the follow‐up was December 1, 2021. The diagnosis of NSCLC was made concerning pathological diagnostic criteria. A flow chart of the enrollment process is displayed (Figure 1). Mortality data were obtained from the hospital registry, and the death time was confirmed by reviewing the electronic medical records or by phone follow‐up. Air quality‐related parameters were referenced to officially published data (http://www.cnemc.cn). The air quality assessment of patients for the 6 months prior to the onset of lung cancer was analyzed by calculating a 6‐month average for every patient. The median follow‐up period was 36.4 months. The database was performed by an independent researcher excluded from the patient care. Informed consent was achieved from their immediate family members or patients themselves. All research projects conformed to the guidelines of the Soochow University Ethics Committee and followed the Declaration of Helsinki. Data from 46 patients with NSCLC at Sichuan Cancer Hospital were applied for external validation.

FIGURE 1.

FIGURE 1

Flow chart for patients’ selection

2.2. Statistical analysis

NCSS‐PASS software version 12.0 was used for sample size calculation. Missing data were filled in using a machine‐learning model with the “mice” package in R. Continuous variables were displayed as mean ± standard deviation and median to the interval. The median was used as the cutoff value. The Mann–Whitney U test and unpaired t tests were applied for comparisons. Categorical variables were displayed as percentages or using the κ2 test. Cumulative mortality was displayed as Kaplan–Meier curves and analyzed by the log‐rank test. Univariate and multivariate survival analyses of overall survival (OS) were estimated by Cox regression models. The significance of variates on prognosis was analyzed visually by forest plots.

Variables with statistical significance in the multifactor analysis were used as predictor variables. The contribution of each factor was calculated and presented in the form of a nomogram plot with 1000 self‐directed validations. When using the Nomogram plot, locate the position of each variable on the axis, then draw a line on the integral axis, sum the scores of all variables, draw the line at the lower line of the Nomogram plot, and draw a line on the total integral axis to determine the events' probability. Calibration was used to assess the consistency of the models developed. The coherence of each model was visualized using scatter plots and analyzed using 1000 bootstrap methods. Statistical analyses were performed using the “ggplot2,” “rms,” “risk regression,” “surminer,” and “PredictABLE” packages of R software (version 4.0.5).

3. RESULTS

A total of 590 patients with NSCLC were enrolled in this investigation. The median age was 64 (58, 70). Among them, 407 (69.0%) cases were male, and 183 (31.0%) patients were female. The mean BMI level was 22.69 ± 3.15. There were 378 (64.0%) cases of adenocarcinoma and 187 (32.0%) cases of squamous carcinoma. Smokers accounted for 51.0% of the included population, with 301 cases. The median KPS score was 90. A total of 416 patients died, with a mortality rate of 71.0%, including 54% in stage I and 78.0% in stage IV, with a significant difference (p < 0.001). The overall median survival was 24.17 (9.9, 50.99) months. It was 38.9 (12.87, 59.8) for stage I patients and 20.4 (9.72, 48.59) for stage IV patients, again with statistical significance (p = 0.012).

In terms of air quality, 6 months before the patient's diagnosis, AQI, air quality classification, PM2.5, NO2, CO, PM10, and O3 all differed from the patient's NSCLC classification. Stage I patients with NSCLC were exposed to an AQI of 86 (81, 91) compared with 90.5 (84, 104) for stage IV patients, with a difference of statistical value (p < 0.001). Similarly, the ambient PM2.5 in Stage I NSCLC patients were 55 (47, 64) compared with 62 (53, 77) in Stage IV patients. PM10 was 72 (66, 87) versus 82 (70, 97) (p < 0.05). The median CO and O3 were 0.91 (0.82, 1.05) and 110 (57, 125.75), respectively.

For long‐term complications, among these 590 patients, there were 224 (38.0%) cases of hypertension, 57 (10.0%) cases of diabetes mellitus, 52 (9.0%) cases of hyperlipidemia, 11 (2.0%) cases of heart failure, and 15 (3.0%) cases of the acute coronary syndrome. Among them, hypertension and hyperlipidemia were statistically different in distribution among different NSCLC stages (Table 1).

TABLE 1.

Study participant characteristics at enrollment

Variables Total (n = 590) Cohort, median (IQR) p value
Stage I (n = 94) Stage II (n = 62) Stage III (n = 121) Stage IV (n = 313)
Baseline data
Age, Median (Q1, Q3) 64 (58, 70) 65 (59, 70) 64 (59, 68.5) 64 (57, 69) 63 (58, 70) 0.851
Gender, n (%) 0.797
Female 183 (31) 27 (29) 17 (27) 41 (34) 98 (31)
Male 407 (69) 66 (71) 45 (73) 80 (66) 216 (69)
BMI, Mean ± SD 22.69 ± 3.15 22.38 ± 3.3 22.62 ± 3.06 22.85 ± 3.15 22.73 ± 3.13 0.732
Pathological type, n (%) 0.485
Adenocarcinoma 378 (64) 57 (61) 36 (58) 77 (64) 208 (66)
Mixed lung cancer 25 (4) 5 (5) 5 (8) 6 (5) 9 (3)
Squamous carcinoma 187 (32) 31 (33) 21 (34) 38 (31) 97 (31)
Smoking, n (%) 0.32
No 289 (49) 40 (43) 26 (42) 63 (52) 160 (51)
Yes 301 (51) 53 (57) 36 (58) 58 (48) 154 (49)
KPS, Median (Q1,Q3) 90 (80, 90) 90 (80, 90) 90 (80, 90) 90 (80, 90) 90 (80, 90) 0.176
Status, n (%) <0.001
Alive 174 (29) 43 (46) 23 (37) 40 (33) 68 (22)
Dead 416 (71) 50 (54) 39 (63) 81 (67) 246 (78)
Overall survival time, Median (Q1,Q3) 24.17 (9.9, 50.99) 38.9 (12.87, 59.8) 18.05 (7.53, 50.99) 28.17 (11.9, 53.8) 20.4 (9.72, 48.59) 0.012
Air quality parameters
AQI, Median (Q1, Q3) 89 (83, 102) 86 (81, 91) 87 (81, 96) 93 (85, 108) 90.5 (84, 104) <0.001
Air stage, n (%) 0.049
Good 438 (74) 78 (84) 50 (81) 82 (68) 228 (73)
Light pollution 95 (16) 11 (12) 10 (16) 21 (17) 53 (17)
Median pollution 57 (10) 4 (4) 2 (3) 18 (15) 33 (11)
PM2.5, Median (Q1, Q3) 61 (52, 76) 55 (47, 64) 58.5 (45.25, 71.75) 69 (55, 81) 62 (53, 77) <0.001
PM10, Median (Q1,Q3) 82 (69, 97) 72 (66, 87) 75 (64, 89.75) 86 (72, 100) 82 (70, 97) 0.002
NO2, Median (Q1,Q3) 41 (25, 50) 38 (25, 46) 35.5 (22.25, 44) 43 (28, 62) 41 (28.25, 50) 0.007
SO2, Median (Q1,Q3) 27 (18, 51) 25 (17, 56) 35 (19, 55.75) 28 (20, 54) 24.5 (18, 47) 0.161
CO, Median (Q1,Q3) 0.91 (0.82, 1.05) 0.88 (0.8, 0.98) 0.89 (0.79, 0.98) 0.97 (0.85, 1.11) 0.91 (0.82, 1.06) 0.002
O3, Median (Q1,Q3) 110 (57, 125.75) 113 (85, 124) 114 (71.25, 130) 70 (52, 116) 111 (57, 129) <0.001
Complications
Hypertension, n (%) 0.037
No 366 (62) 49 (53) 47 (76) 76 (63) 194 (62)
Yes 224 (38) 44 (47) 15 (24) 45 (37) 120 (38)
Diabetes, n (%) 0.323
No 533 (90) 82 (88) 57 (92) 105 (87) 289 (92)
Yes 57 (10) 11 (12) 5 (8) 16 (13) 25 (8)
Hyperlipemia, n (%) 0.024
No 538 (91) 88 (95) 57 (92) 102 (84) 291 (93)
Yes 52 (9) 5 (5) 5 (8) 19 (16) 23 (7)
Heart. failure, n (%) 0.111
No 579 (98) 89 (96) 61 (98) 121 (100) 308 (98)
Yes 11 (2) 4 (4) 1 (2) 0 (0) 6 (2)
ACS, n (%) 0.813
No 575 (97) 90 (97) 60 (97) 119 (98) 306 (97)
Yes 15 (3) 3 (3) 2 (3) 2 (2) 8 (3)

Abbreviation: ACS, Acute Coronary Syndromes; AQI, air quality index; BMI, Body Mass Index; IQR, interquartile range; KPS, Karnofsky Performance Status.

Kaplan–Meier curves showed that among NSCLC patients, those exposed to AQI > 89 in the 6 months prior to diagnosis had lower overall survival than controls (log‐rank, p = 0.036) (Figure 2A). Similarly, patients exposed to PM2.5 levels above 60 had lower overall survival than controls (log‐rank, p = 0.029) (Figure 2B). To explore the impact of air quality on tumor staging and long‐term survival in NSCLC patients, we performed univariate analysis of the above factors. The data showed that exposure to high levels of PM2.5 in NSCLC patients was a risk factor for overall patient survival (HR = 1.35, 95% CI 1.11–1.64, p = 0.002), whereas AQI (OR = 2.61, 95% CI 1.78–3.86, p < 0.001), air stage (OR = 1.91, 95% CI 1.22–3.09, p = 0.006), PM2.5 (OR = 2.32, 95% CI 1.60–3.41, p < 0.001), PM10 (OR = 1.45. 95% CI 1.01–2.11, p = 0.048), NO2 (OR = 1.48, 95% CI 1.02–2.15, p = 0.038), and elevated CO levels (OR = 1.47, 95% CI 1.02–2.14, p = 0.041) were risk factors for higher tumor stage (stage III or IV) in NSCLC patients. In contrast, elevated O3 levels were an effective protective factor for the above endpoint events (OR = 0.65, 95% CI 0.45–0.94, p = 0.021) (Table 2). Based on statistical results and clinical experience, we included factors with potential predictive value in the multifactorial analysis. The results showed that elevated PM2.5 levels (HR = 1.53, 95% CI 1.13–2.07, p = 0.006) were likewise an independent risk factor for long‐term survival (Figure 3A). In addition, elevated AQI levels (HR = 2.61, 95% CI 1.35–5.24, p = 0.005) were an independent risk factor for achieving higher tumor stage (stage III or IV) in NSCLC patients (Figure 3B).

FIGURE 2.

FIGURE 2

Kaplan–Meier curves for NSCLC patients with different air quality exposure. (A) Kaplan–Meier curves for OS in patients in the AQI≤89 and AQI >89 groups. (B) Kaplan–Meier curves for OS in different PM2.5 groups

TABLE 2.

Univariate regression analysis on NSCLC patients for different endpoints

Variants OS Stage III or IV
HR p value OR p value
Age (years), >65 versus ≤65 1.38 [1.14, 1.67] 0.001 0.92 [0.64, 1.34] 0.668
Gender, male versus female 1.52 [1.22, 1.89] <0.001 0.84 [0.56, 1.26] 0.41
Pathological type, adenocarcinoma versus others 0.75 [0.61, 0.91] 0.004 1.27 [0.87, 1.84] 0.219
Smoking, yes versus no 1.32 [1.09, 1.60] 0.005 0.70 [0.49, 1.02] 0.064
KPS score, <90, versus >90 2.40 [1.97, 2.93] <0.001 1.07 [0.74, 1.56] 0.707
AQI, >89 versus <89 1.23 [1.01, 1.49] 0.036 2.61 [1.78, 3.86] <0.001
Air stage, light or median pollution versus good 1.07 [0.86, 1.33] 0.541 1.91 [1.22, 3.09] 0.006
PM2.5, > 60 versus < 60 1.35 [1.11, 1.64] 0.002 2.32 [1.60, 3.41] <0.001
PM10, >82 versus <82 1.19 [0.98, 1.44] 0.082 1.45 [1.01, 2.11] 0.048
NO2, >41 versus <41 1.03 [0.85, 1.25] 0.782 1.48 [1.02, 2.15] 0.038
SO2, >27 versus <27 0.96 [0.79, 1.17] 0.707 0.96 [0.67, 1.39] 0.833
CO, >0.91 versus <0.91 1.02 [0.84, 1.24] 0.81 1.47 [1.02, 2.14] 0.041
O3, >110 versus <110 0.92 [0.76, 1.12] 0.403 0.65 [0.45, 0.94] 0.021
Hypertension, yes versus no 1.03 [0.84, 1.25] 0.788 0.99 [0.68, 1.46] 0.977
Diabetes, yes versus no 1.14 [0.83, 1.57] 0.427 0.90 [0.50, 1.71] 0.745
Hyperlipemia, yes versus no 0.63 [0.44, 0.91] 0.014 1.55 [0.79, 3.34] 0.23
Heart failure, yes versus no 1.25 [0.62, 2.53] 0.526 0.42 [0.12, 1.47] 0.156
ACS, yes versus no 1.18 [0.63, 2.22] 0.601 0.71 [0.25, 2.30] 0.531
Stage III or IV, yes versus no 1.39 [1.10, 1.75] 0.006 — —

Abbreviation: ACS, Acute Coronary Syndromes; AQI, air quality index; BMI, Body Mass Index; IQR, interquartile range; KPS, Karnofsky Performance Status.

FIGURE 3.

FIGURE 3

Forest plot for multifactorial analysis of different endpoints in patients with NSCLC. (A) Forest plot for multifactor analysis of the risk of overall mortality. (B) Forest plot for multifactor analysis of the risk of stage III or IV NSCLC

Overall survival at 3 and 5 years is an essential metric for assessing long‐term survival in patients with NSCLC. The successful prediction may help clinicians in the treatment selection of patients. Based on multivariate regression, we selected age, gender, KPS score, PM2.5, and the presence of hyperlipidemia to build prediction models. To quantify the contribution of each factor to the 5‐year overall survival, we generated a model displayed by nomogram as shown in Figure 4A. The calibration curve showed good calibration of the model (C‐statistic = 0.758) (Figure 4B). We collected 46 NSCLC patients from Sichuan Cancer Hospital in the external validation step. The ROC curve showed an AUC of 0.758 (0.718–0.797) for predicting 5‐year overall survival compared with an AUC of 0.724 (0.684–0.763) for the external validation data (Figure 5).

FIGURE 4.

FIGURE 4

Nomogram of 5‐year survival estimates in patients with NSCLC and its predictive performance. (A) Nomogram of 5‐year survival estimates in patients with NSCLC. (B). Validation of the nomogram in estimating the predictive performance of patients with NSCLC (n = 590)

FIGURE 5.

FIGURE 5

ROC curve for derivation and external validation

4. DISCUSSION

This cohort study demonstrated the value of air quality parameters, especially AQI and PM2.5, in reflecting long‐term survival and tumor progression in NSCLC patients. Elevated AQI as well as PM2.5 levels are detrimental to the long‐term prognosis of NSCLC patients. We also developed a prediction model for long‐term survival events in NSCLC patients based on PM2.5 levels to facilitate clinicians' decision‐making.

A meta‐analysis led by Hamra et al. showed that both PM2.5 and PM10 contributed to the development of lung cancer, with PM2.5 having a greater effect. The meta‐estimates of adenocarcinoma associated with PM2.5 and PM10 were 1.40 (95% CI: 1.07, 1.83) and 1.29 (95% CI: 1.02, 1.63), respectively. 23 However, there are fewer studies related to the effects of these two air pollutants on OS. Our results show that PM2.5 has a greater prognostic impact on NSCLC compared with PM10.

Several studies have found a significant relationship between PM2.5 and lung disease. 24 PM2.5 is an air pollutant of ≤2.5 μm in diameter that is characterized by large surface area, small particle size, 25 and high toxin absorption capacity. 26 These properties give PM2.5 the potential to invade the minor respiratory tracts including alveolar tissues. PM2.5 included metals, black carbon, sulfates, polycyclic aromatic hydrocarbons, nitrates, and vehicle exhaust particles. 27 It has been shown that exposing mice to PM2.5 results in a greater tendency to deposit PM2.5 into lung problems than other metal pollutants. 28 Many biological activities, including coagulation homeostasis, cardiopulmonary function, and cytokine formation, are altered by PM2.5. 29 Several studies have shown that PM2.5 may trigger chronic obstructive pulmonary disease (COPD) and lung cancer by activating AMP‐activated protein kinase (AMPK) catalytic subunit α1 and related signaling pathways such as signal transducer and activator of transcription (STAT)‐1. 30 A small number of studies have also shown that nuclear factor‐κB (NF‐κB), mitogen‐activated protein kinase (MAPK), vascular endothelial growth factor receptor (VEGF), and interleukin (IL)‐8 signaling are involved in PM2.5‐induced lung injury. 31

Our study shows that PM2.5 is a risk factor for long‐term survival and high stage of lung cancer (stage III or stage IV) in NSCLC patients and is an independent risk factor for survival. These patients who are exposed to high levels of PM2.5 for a long time often suffer from lung inflammation. Examples include asthma and COPD. Therefore, we speculate that the predisposing effect of PM2.5 on lung cancer may be related to inflammatory development. The tumor microenvironment is essential for tumorigenesis and progression, especially in NSCLC. 32 The production of cytokines, inflammatory cells, and angiogenesis has been recognized to be associated with tumor cell proliferation and tumor metastasis. 33 Many transcription and inflammatory factors play a role in the NSCLC tumor microenvironment including NF‐κB, STAT‐3, interleukin‐6 and ‐1β, and tumor necrosis factor‐alpha (TNF‐α). 34 Exposure to PM2.5 can increase the proliferative and mobility of H1299 and A549 cells, and MMP‐1 and IL‐1β may be responsible for the effects of PM2.5. 35 The polarization of alveolar macrophages may play a role in tumor growth and angiogenesis through the secretion of VEGF and IL‐8. 36 Previous studies have shown that PM2.5 can induce the release of various pro‐inflammatory cytokines, including TNF‐α, granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), and IL‐6, from HBE cells and macrophages, leading to airway inflammation. 37 , 38 , 39 Thus, PM2.5‐induced alterations in the tumor microenvironment may promote tumor growth and metastasis by triggering angiogenic and inflammatory responses. Therefore, for NSCLC patients, we need to provide them with a clean environment or use devices such as air purifiers to improve air quality. It will benefit the long‐term quality of survival of these patients. There are few studies on the correlation between SCLC and environmental pollution. We found that previous studies showed that radon gas was associated with the occurrence of SCLC. Krewski et al. analyzed a pooled study of seven case–control studies and found a correlation between residential radon exposure and lung cancer, with the strongest relationship with SCLC. 40 In addition, a case–control study in New Jersey conducted by Wilcox et al. found no significant increase in lung cancer risk with increasing radon levels. However, radon exposure showed a stronger effect on SCLC in both men and women. 41

This study remains a retrospective cohort study. The air quality of each patient's environment was not entirely consistent, which led to the limited evidence‐based nature of this study. Future multicenter clinical trials are needed to demonstrate the impact of air quality, especially AQI and PM2.5, on long‐term survival in NSCLC patients.

5. CONCLUSION

Our results show that PM2.5 and AQI levels affect disease progression and long‐term survival of NSCLC patients. An overall survival prediction model based on PM2.5 levels could help clinicians predict the mortality in NSCLC patients.

CONFLICT OF INTEREST

The authors declare that there are no competing interests.

AUTHORS' CONTRIBUTION

LJ and WXY conducted the analysis and drafted the manuscript. GL completed studies and analyzed data. QLY, XMQ, ZHC, and XL contributed to the manuscript writing and data analysis. PWY, YZY, and ZXL added to the collection and analysis of clinical data. ZDX and JJH contributed to the research design, data analysis, writing the manuscript, and supervision of the investigation.

ETHICAL APPROVAL AND CONSENT TO PARTICIPATE

The Clinical Research Ethics Committee approved clinical data with the Affiliated Dushu Lake Hospital of Soochow University.

CONSENT FOR PUBLICATION

We have got consent from all the authors for publication.

ACKNOWLEDGMENTS

We thanks to the Priority Academic Program Development of Jiangsu Higher Education Institutions for providing supports.

Li J, Wei X, Gu L, et al. Elevated air quality index and fine particulate matter levels contribute to the poor prognosis and progression of nonsmall‐cell lung cancer: A cohort study combined with external validation. Cancer Med. 2022;11(17):3272–3281. doi: 10.1002/cam4.4701

Jing Li, Xiaoying Wei and Ling Gu contributed equally.

Funding information

This study was supported by the Social Development Project of Jiangsu Province, China in 2016 (No. BE2016672) and the Project of Hygiene and Health Committee of Jiangsu Province, China (No. H2019028).

Contributor Information

Daxiong Zeng, Email: jiangjunhong1969@suda.edu.cn, Email: darxzeng@126.com.

Junhong Jiang, Email: jiangjunhong1969@suda.edu.cn.

DATA AVAILABILITY STATEMENT

Original data is available if necessary.

REFERENCES

  • 1. Guarnieri M, Balmes JR. Outdoor air pollution and asthma. Lancet. 2014;383(9928):1581‐1592. doi: 10.1016/S0140-6736(14)60617-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Lelieveld J, Evans JS, Fnais M, Giannadaki D, Pozzer A. The contribution of outdoor air pollution sources to premature mortality on a global scale. Nature. 2015;525(7569):367‐371. doi: 10.1038/nature15371 [DOI] [PubMed] [Google Scholar]
  • 3. Gordon SB, Bruce NG, Grigg J, et al. Respiratory risks from household air pollution in low and middle income countries. Lancet Respir Med. 2014;2(10):823‐860. doi: 10.1016/S2213-2600(14)70168-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Churg A, Brauer M, del Carmen Avila‐Casado M, Fortoul TI, Wright JL. Chronic exposure to high levels of particulate air pollution and small airway remodeling. Environ Health Perspect. 2003;111(5):714‐718. doi: 10.1289/ehp.6042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc. 2004;1(4):315‐320. doi: 10.1513/pats.200409-046TA [DOI] [PubMed] [Google Scholar]
  • 6. Lipworth B, Manoharan A, Anderson W. Unlocking the quiet zone: the small airway asthma phenotype. Lancet Respir Med. 2014;2(6):497‐506. doi: 10.1016/S2213-2600(14)70103-1 [DOI] [PubMed] [Google Scholar]
  • 7. Macklem PT. The physiology of small airways. Am J Respir Crit Care Med. 1998;157(5 Pt 2):S181‐S183. doi: 10.1164/ajrccm.157.5.rsaa-2 [DOI] [PubMed] [Google Scholar]
  • 8. Ingram RH Jr. Physiological assessment of inflammation in the peripheral lung of asthmatic patients. Lung. 1990;168(5):237‐247. doi: 10.1007/BF02719700 [DOI] [PubMed] [Google Scholar]
  • 9. Yanai M, Sekizawa K, Ohrui T, Sasaki H, Takishima T. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol (1985). 1992;72(3):1016‐1023. doi: 10.1152/jappl.1992.72.3.1016 [DOI] [PubMed] [Google Scholar]
  • 10. de Magalhaes SS, dos Santos MA, da Silva OM, et al. Inflammatory cell mapping of the respiratory tract in fatal asthma. Clin Exp Allergy. 2005;35(5):602‐611. doi: 10.1111/j.1365-2222.2005.02235.x [DOI] [PubMed] [Google Scholar]
  • 11. Hamid Q, Song Y, Kotsimbos TC, et al. Inflammation of small airways in asthma. J Allergy Clin Immunol. 1997;100(1):44‐51. doi: 10.1016/s0091-6749(97)70193-3 [DOI] [PubMed] [Google Scholar]
  • 12. Li P, Xin J, Wang Y, et al. The acute effects of fine particles on respiratory mortality and morbidity in Beijing, 2004‐2009. Environ Sci Pollut Res Int. 2013;20(9):6433‐6444. doi: 10.1007/s11356-013-1688-8 [DOI] [PubMed] [Google Scholar]
  • 13. O'Connor GT, Neas L, Vaughn B, et al. Acute respiratory health effects of air pollution on children with asthma in US inner cities. J Allergy Clin Immunol. 2008;121(5):1133‐1139.e1. doi: 10.1016/j.jaci.2008.02.020 [DOI] [PubMed] [Google Scholar]
  • 14. Delfino RJ, Staimer N, Gillen D, et al. Personal and ambient air pollution is associated with increased exhaled nitric oxide in children with asthma. Environ Health Perspect. 2006;114(11):1736‐1743. doi: 10.1289/ehp.9141 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69‐90. doi: 10.3322/caac.20107 [DOI] [PubMed] [Google Scholar]
  • 16. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11‐30. doi: 10.3322/caac.21166 [DOI] [PubMed] [Google Scholar]
  • 17. Tang J, Salama R, Gadgeel SM, Sarkar FH, Ahmad A. Erlotinib resistance in lung cancer: current progress and future perspectives. Front Pharmacol. 2013;4:15. doi: 10.3389/fphar.2013.00015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Araujo A, Ribeiro R, Azevedo I, et al. Genetic polymorphisms of the epidermal growth factor and related receptor in non‐small cell lung cancer‐‐a review of the literature. Oncologist. 2007;12(2):201‐210. doi: 10.1634/theoncologist.12-2-201 [DOI] [PubMed] [Google Scholar]
  • 19. Peebles KA, Lee JM, Mao JT, et al. Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev Anticancer Ther. 2007;7(10):1405‐1421. doi: 10.1586/14737140.7.10.1405 [DOI] [PubMed] [Google Scholar]
  • 20. Wu K, House L, Liu W, Cho WC. Personalized targeted therapy for lung cancer. Int J Mol Sci. 2012;13(9):11471‐11496. doi: 10.3390/ijms130911471 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Bremnes RM, Al‐Shibli K, Donnem T, et al. The role of tumor‐infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non‐small cell lung cancer. J Thorac Oncol. 2011;6(4):824‐833. doi: 10.1097/JTO.0b013e3182037b76 [DOI] [PubMed] [Google Scholar]
  • 22. Tiotiu AI, Novakova P, Nedeva D, et al. Impact of air pollution on asthma outcomes. Int J Environ Res Public Health. 2020;17(17):6212. doi: 10.3390/ijerph17176212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Hamra GB, Guha N, Cohen A, et al. Outdoor particulate matter exposure and lung cancer: a systematic review and meta‐analysis. Environ Health Perspect. 2014;122(9):906‐911. doi: 10.1289/ehp.1408092 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Du P, Du R, Ren W, Lu Z, Fu P. Seasonal variation characteristic of inhalable microbial communities in PM2.5 in Beijing city, China. Sci Total Environ. 2018;610–611:308‐315. doi: 10.1016/j.scitotenv.2017.07.097 [DOI] [PubMed] [Google Scholar]
  • 25. Kim Y, Seo J, Kim JY, Lee JY, Kim H, Kim BM. Characterization of PM2.5 and identification of transported secondary and biomass burning contribution in Seoul, Korea. Environ Sci Pollut Res Int. 2018;25(5):4330‐4343. doi: 10.1007/s11356-017-0772-x [DOI] [PubMed] [Google Scholar]
  • 26. Bell ML, Dominici F, Ebisu K, Zeger SL, Samet JM. Spatial and temporal variation in PM(2.5) chemical composition in the United States for health effects studies. Environ Health Perspect. 2007;115(7):989‐995. doi: 10.1289/ehp.9621 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Li Q, Liu H, Alattar M, et al. The preferential accumulation of heavy metals in different tissues following frequent respiratory exposure to PM2.5 in rats. Sci Rep. 2015;5:16936. doi: 10.1038/srep16936 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Jiang S, Bo L, Du X, et al. CARD9‐mediated ambient PM2.5‐induced pulmonary injury is associated with Th17 cell. Toxicol Lett. 2017;273:36‐43. doi: 10.1016/j.toxlet.2017.03.015 [DOI] [PubMed] [Google Scholar]
  • 29. Falcon‐Rodriguez CI, Osornio‐Vargas AR, Sada‐Ovalle I, Segura‐Medina P. Aeroparticles, composition, and lung diseases. Front Immunol. 2016;7:3. doi: 10.3389/fimmu.2016.00003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Jeong SC, Cho Y, Song MK, Lee E, Ryu JC. Epidermal growth factor receptor (EGFR)‐MAPK‐nuclear factor(NF)‐kappaB‐IL8: a possible mechanism of particulate matter(PM) 2.5‐induced lung toxicity. Environ Toxicol. 2017;32(5):1628‐1636. doi: 10.1002/tox.22390 [DOI] [PubMed] [Google Scholar]
  • 31. Graves EE, Maity A, Le QT. The tumor microenvironment in non‐small‐cell lung cancer. Semin Radiat Oncol. 2010;20(3):156‐163. doi: 10.1016/j.semradonc.2010.01.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Vendramini‐Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. Curr Pharm des. 2012;18(26):3831‐3852. doi: 10.2174/138161212802083707 [DOI] [PubMed] [Google Scholar]
  • 33. Cho WC, Kwan CK, Yau S, So PP, Poon PC, Au JS. The role of inflammation in the pathogenesis of lung cancer. Expert Opin Ther Targets. 2011;15(9):1127‐1137. doi: 10.1517/14728222.2011.599801 [DOI] [PubMed] [Google Scholar]
  • 34. Yang B, Chen D, Zhao H, Xiao C. The effects for PM2.5 exposure on non‐small‐cell lung cancer induced motility and proliferation. Springerplus. 2016;5(1):2059. doi: 10.1186/s40064-016-3734-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Almatroodi SA, McDonald CF, Pouniotis DS. Alveolar macrophage polarisation in lung cancer. Lung Cancer Int. 2014;2014:1‐9. doi: 10.1155/2014/721087 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Zhou Z, Liu Y, Duan F, et al. Transcriptomic analyses of the biological effects of airborne PM2.5 exposure on human bronchial epithelial cells. PLoS One. 2015;10(9):e0138267. doi: 10.1371/journal.pone.0138267 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Baulig A, Blanchet S, Rumelhard M, Lacroix G, Marano F, Baeza‐Squiban A. Fine urban atmospheric particulate matter modulates inflammatory gene and protein expression in human bronchial epithelial cells. Front Biosci. 2007;12:771‐782. doi: 10.2741/2100 [DOI] [PubMed] [Google Scholar]
  • 38. Gualtieri M, Mantecca P, Cetta F, Camatini M. Organic compounds in tire particle induce reactive oxygen species and heat‐shock proteins in the human alveolar cell line A549. Environ Int. 2008;34(4):437‐442. doi: 10.1016/j.envint.2007.09.010 [DOI] [PubMed] [Google Scholar]
  • 39. Combined analysis of 7 north American case‐control studies. Epidemiology. 2005;16(2):137‐145. doi: 10.1097/01.ede.0000152522.80261.e3 [DOI] [PubMed] [Google Scholar]
  • 40. Wilcox HB, Al‐Zoughool M, Garner MJ, et al. Case‐control study of radon and lung cancer in New Jersey. Radiat Prot Dosimetry. 2008;128(2):169‐179. doi: 10.1093/rpd/ncm330 [DOI] [PubMed] [Google Scholar]
  • 41. Hamid QA. Peripheral inflammation is more important than central inflammation. Respir Med. 1997;91(Suppl A):11‐12. doi: 10.1016/s0954-6111(97)90098-6 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Original data is available if necessary.


Articles from Cancer Medicine are provided here courtesy of Wiley

RESOURCES